Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Higher consumption of added sugars in processed foods associated with lower levels of HDL-C: Study

Consuming a higher amount of added sugars in processed or prepared foods is associated with lower levels of high-density lipoprotein cholesterol and higher levels of triglycerides, which are important risk factors for cardiovascular disease, according to a study in the April 21 issue of JAMA.

21 Apr 2010

Added sugars in diet related to high cholesterol and increased risk of heart disease, say researchers

According to researchers, an average American gets 16% of calories from the sugar in their diet. These may be sugars added to processed foods during manufacture.

21 Apr 2010

Patients dismissed from hospital with noncardiac chest pain continue to experience cardiac events: Study

The growing number of Americans with cardiovascular disease has caused a heightened sensitivity in the evaluation of chest pain. In a study published in the April issue of Mayo Clinic Proceedings researchers reported that patients dismissed from the hospital with noncardiac chest pain continue to experience cardiac events, which may highlight a need for more aggressive cardiovascular risk factor management in this population.

21 Apr 2010

Gamma-prime fibrinogen test can help better predict people at risk for heart attack

A simple blood test can identify people who are at risk for a heart attack, including thousands who don't have high cholesterol, according to researchers at Oregon Health & Science University.

20 Apr 2010

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that independent researchers presented results showing that XOMA's antibody to interleukin-1 beta (IL-1 beta), XOMA 052, was highly effective in reducing production of a protein that supports the proliferation of cancerous human myeloma cells in vitro.

20 Apr 2010

Statin use may increase risk of developing benign colorectal tumors: APC trial

Statins did not protect patients against colorectal adenomas, which are benign precursors of colorectal cancer, according to results of a secondary analysis of the Adenoma Prevention with Celecoxib trial. In a population at high-risk for developing these lesions, results of this analysis suggested statin use may increase the risk of developing benign colorectal tumors.

20 Apr 2010

Even modest weight loss brings many health benefits

There have been repeated warnings related to the growing obese and diabetes related population in Australia. Studies have shown that nearly 50% Australians are either obese or overweight and thus suffer from its ill effects like heart disease, high cholesterol and type II diabetes.

20 Apr 2010

SPI-Bio to distribute and sell Aterovax's sPLA2 activity test in Europe

Aterovax SA, a company developing innovative products for atherosclerosis, today announced the signing of a 3 year, exclusive agreement with SPI-Bio, a specialist distributor of products and services in drug development, to distribute and sell Aterovax's sPLA2 activity test in Europe to academic and research laboratories for research use.

19 Apr 2010

Caliper Life Sciences introduces Quantum FX stand-alone microCT system for preclinical imaging

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today announced the Quantum FX, a stand-alone microCT system for preclinical imaging. Introduced at the American Association for Cancer Research Annual Meeting 2010, the Quantum FX is a low dose, microCT system that provides researchers with a 3-dimensional anatomical view of disease activity, tumor development and therapeutic response over multiple time points during the course of a study.

19 Apr 2010

Trans fats back on the agenda in UK

Dariush Mozzaffarian and Meir J Stamper, wrote an article in the British Medical Journal urging the government to ban industrial trans fatty acids or TFAs. This adds to the plea of doctors and medical charities across the country, who want to follow the example of Denmark and New York City where TFAs have been eradicated without affecting the price, taste or availability of products.

19 Apr 2010

VisEn Medical expands FMT imaging platform

VisEn Medical Inc., a leader in fluorescence imaging solutions from research through medicine, announced today that it has expanded its leading FMT imaging platform with an FMT™ Multi-Species Imaging Module, to extend FMT imaging and related applications into larger preclinical animal models. VisEn also announced that it will be presenting new study results from its recently-launched Cat B 750 FAST™ and Annexin-Vivo™ fluorescence imaging agents at the AACR 101st Annual Meeting.

16 Apr 2010

Calorie restriction may help people to lead longer and healthier lives

Organisms from yeast to rodents to humans all benefit from cutting calories. In less complex organisms, restricting calories can double or even triple lifespan. It's not yet clear just how much longer calorie restriction might help humans live, but those who practice the strict diet hope to survive past 100 years old.

16 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

New research investigating neurological decline in a population of "super healthy" elderly subjects found that the decline in neurological function of the peripheral nervous system attributed to aging may be related to metabolic factors, such as blood sugar levels, even if these factors are within the normal range.

16 Apr 2010

LOTS results of Myozyme in older children and adults with Pompe disease published

Genzyme Corp. today announced that the results from its Late-Onset Treatment Study have been published in today's New England Journal of Medicine. The study was undertaken to evaluate the safety and efficacy of Myozyme (alglucosidase alfa) in older children and adults with Pompe disease.

16 Apr 2010

Certain genetic variations linked to tooth decay, periodontitis

Certain genetic variations may be linked to higher rates of tooth decay and aggressive periodontitis, according to two recently published papers by researchers at the University of Pittsburgh School of Dental Medicine and their collaborators.

16 Apr 2010

Regulus Therapeutics' metabolic disease program data presented at Diabetes Keystone Symposium

Regulus Therapeutics Inc. today announced that new data from its metabolic disease program were presented at the "Diabetes" Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice.

16 Apr 2010

Takeda Pharmaceutical offers milestone payment to XOMA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced it has received a $1 million milestone payment from Takeda Pharmaceutical Company Limited for achieving a pre-established preclinical milestone under the companies' 2006 collaboration agreement, which also calls for additional future milestone payments and royalties on product sales.

16 Apr 2010

EU Joint Programming initiative to tackle neurodegenerative diseases

Leading researchers from across Europe will gather today in Stockholm to develop a European-wide research strategy to tackle neurodegenerative diseases such as Alzheimer's and Parkinson's Disease.

15 Apr 2010

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme Corporation today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The data were presented at the American Academy of Neurology annual meeting.

15 Apr 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Higher consumption of added sugars in processed foods associated with lower levels of HDL-C: Study

Added sugars in diet related to high cholesterol and increased risk of heart disease, say researchers

Patients dismissed from hospital with noncardiac chest pain continue to experience cardiac events: Study

Gamma-prime fibrinogen test can help better predict people at risk for heart attack

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

Statin use may increase risk of developing benign colorectal tumors: APC trial

Even modest weight loss brings many health benefits

SPI-Bio to distribute and sell Aterovax's sPLA2 activity test in Europe

Caliper Life Sciences introduces Quantum FX stand-alone microCT system for preclinical imaging

Trans fats back on the agenda in UK

VisEn Medical expands FMT imaging platform

Calorie restriction may help people to lead longer and healthier lives

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

LOTS results of Myozyme in older children and adults with Pompe disease published

Certain genetic variations linked to tooth decay, periodontitis

Regulus Therapeutics' metabolic disease program data presented at Diabetes Keystone Symposium

Takeda Pharmaceutical offers milestone payment to XOMA

EU Joint Programming initiative to tackle neurodegenerative diseases

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Innovation in neuroscience drug discovery - eBook eBook

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Leveraging the Radian ASAP in standard casework

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Innovation in neuroscience drug discovery - eBook eBook

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Leveraging the Radian ASAP in standard casework

Newsletters you may be interested in